相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy
Cedric S. Cui et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)
A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models
Vinod Kumar et al.
JOURNAL OF NEUROCHEMISTRY (2021)
Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors
Shubhi Pandey et al.
MOLECULAR CELL (2021)
Avacopan for the Treatment of ANCA-Associated Vasculitis
David R. W. Jayne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation
Chao Zhang et al.
SMALL (2021)
Optimisation of a Microfluidic Method for the Delivery of a Small Peptide
Felicity Y. Han et al.
PHARMACEUTICS (2021)
Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility
Sih Min Tan et al.
DIABETES (2020)
Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice
Vinod Kumar et al.
ACS OMEGA (2020)
Metabolic Fingerprinting on Synthetic Alloys for Medulloblastoma Diagnosis and Radiotherapy Evaluation
Jing Cao et al.
ADVANCED MATERIALS (2020)
Emerging Insights into the Structure and Function of Complement C5a Receptors
Shubhi Pandey et al.
TRENDS IN BIOCHEMICAL SCIENCES (2020)
Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function
Xaria X. Li et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Recent advances on peptide-based theranostic nanomaterials
Lei Rong et al.
VIEW (2020)
PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters
Karol Yesenia Hernandez-Giottonini et al.
RSC ADVANCES (2020)
C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma
Jamileh A. Nabizadeh et al.
FASEB JOURNAL (2019)
The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity
Xaria X. Li et al.
JOURNAL OF IMMUNOLOGY (2019)
Clinical promise of next-generation complement therapeutics
Dimitrios C. Mastellos et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
Ruba Ismail et al.
PHARMACEUTICS (2019)
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Sarah M. Carpanini et al.
FRONTIERS IN IMMUNOLOGY (2019)
Synergistic effect of PLGA nanoparticles and submicron triglyceride droplets in enhancing the intestinal solubilisation of a lipophilic weak base
Paul Joyce et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice
Vinod Kumar et al.
SCIENTIFIC REPORTS (2018)
Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis
Iliana Michailidou et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Investigation of Effective Parameters on Size of Paclitaxel Loaded PLGA Nanoparticles
Fatemeh Madani et al.
ADVANCED PHARMACEUTICAL BULLETIN (2018)
Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
Md. K. Anwer et al.
FRONTIERS IN PHARMACOLOGY (2017)
Fundamental studies on throughput capacities of hydrodynamic flow-focusing microfluidics for producing monodisperse polymer nanoparticles
Thejus Baby et al.
CHEMICAL ENGINEERING SCIENCE (2017)
Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis
John D. Lee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Peptide/protein vaccine delivery system based on PLGA particles
Mojgan Allahyari et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
C5a and pain development: An old molecule, a new target
Andreza U. Quadros et al.
PHARMACOLOGICAL RESEARCH (2016)
A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives
Abdul Muheem et al.
SAUDI PHARMACEUTICAL JOURNAL (2016)
Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading
Felicity Y. Han et al.
FRONTIERS IN PHARMACOLOGY (2016)
Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit
William A. Banks et al.
JOURNAL OF NEUROINFLAMMATION (2015)
The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury
Faith H. Brennan et al.
JOURNAL OF NEUROSCIENCE (2015)
Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain
Felicity Y. Han et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and β-arrestin recruitment
Daniel E. Croker et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Complement and blood-brain barrier integrity
Alexander Jacob et al.
MOLECULAR IMMUNOLOGY (2014)
Design and Optimization of PLGA-Based Diclofenac Loaded Nanoparticles
Dustin L. Cooper et al.
PLOS ONE (2014)
The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10
U. Jain et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
The Future of Peptide-based Drugs
David J. Craik et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
PLGA-based nanoparticles: An overview of biomedical applications
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2012)
The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen
Amit K. Jain et al.
BIOMATERIALS (2011)
Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice
Helga D. Manthey et al.
FASEB JOURNAL (2011)
C5a/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-κB
Alexander Jacob et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Inhibiting the C5-C5a receptor axis
Trent M. Woodruff et al.
MOLECULAR IMMUNOLOGY (2011)
C5a alters blood-brain barrier integrity in experimental lupus
Alexander Jacob et al.
FASEB JOURNAL (2010)
The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System
Trent M. Woodruff et al.
NEUROMOLECULAR MEDICINE (2010)
Therapeutic application of peptides and proteins: parenteral forever?
Zuzana Antosova et al.
TRENDS IN BIOTECHNOLOGY (2009)
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis
Michael A. Flierl et al.
CRITICAL CARE (2009)
Neutrophil mobilization and clearance in the bone marrow
Rebecca C. Furze et al.
IMMUNOLOGY (2008)
Past, present, and future technologies for oral delivery of therapeutic proteins
Rajesh Singh et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Formation and enhanced biocidal activity of water-dispersable organic nanoparticles
Haifei Zhang et al.
NATURE NANOTECHNOLOGY (2008)
Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation
C. E. Vergunst et al.
RHEUMATOLOGY (2007)
Complement-targeted therapeutics
Daniel Ricklin et al.
NATURE BIOTECHNOLOGY (2007)
Function, structure and therapeutic potential of complement C5a receptors
P. N. Monk et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration
Trent M. Woodruff et al.
FASEB JOURNAL (2006)
Recent developments in C5/C5a inhibitors
LM Proctor et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2006)
Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier
N Nonaka et al.
EXPERIMENTAL NEUROLOGY (2005)
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity
DR March et al.
MOLECULAR PHARMACOLOGY (2004)
In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668
T Ameller et al.
INTERNATIONAL JOURNAL OF CANCER (2003)